Recently, Fan Jincheng, director of the Health Service Committee of Shanghai Modern Service Industry Federation, visited the headquarters of Sidi Diagnostics. Xiong Lei, founder and chairman of Sidi Diagnostics, and Cheng Jie, director of the Public Affairs Department, warmly received Director Fan and his delegation. Also present were Xu Yuying, deputy director of the Health Service Committee, and Ren Bo, deputy director and secretary general.
In the afternoon of the same day, Xiong Lei accompanied Fan Jincheng and his entourage to visit Chen Kaixian, an academician of the Chinese Academy of Sciences. Xiong Lei reported to Academician Chen Kaixian on the R&D direction and achievements of Idea Di Diagnostics, especially the active exploration and innovative breakthroughs in relying on exosome technology to carry out early diagnosis of diseases. Academician Chen affirmed the innovative exploration of Idea Di Diagnostics, and encouraged Idea Di Diagnostics to study in-depth Xi implement the instructions of the company during the inspection of Shanghai, take scientific and technological innovation as the guide, strengthen key core technology research, and continue to develop medical products that fill the gaps in clinical needs and have significant influence.
Founded in 2010 and headquartered in Shanghai, Idea Diagnostics is one of the pioneers in the field of precision medicine in China. At present, the company's diagnostic business covers the whole life cycle of tumor diagnosis of "early tumor diagnosis + tumor companion diagnosis + tumor dynamic monitoring". In addition, the company is also in the field of infection molecular diagnosis, and its products and solutions have been applied in China and more than 70 countries and regions around the world. In order to promote the global R&D layout of products, Sidi Diagnostics has set up R&D centers in China and overseas, with nearly 300 R&D personnel, accounting for more than 30% of the company's employees. The company has a number of honorary qualifications such as national specialized, special and new little giant, high-tech enterprise, Shanghai enterprise technology center and Shanghai science and technology little giant enterprise.
Idea Di Diagnostics has established a comprehensive R&D platform including equipment engineering, electrical, life science technology, materials science and artificial intelligence data analysis, and has the ability to realize fully automated R&D and manufacturing operations and intelligent data processing in the field of accurate diagnosis. Thoughtdi Diagnostics has applied for and obtained nearly 400 patents. In addition, Idea Di Diagnostics also has the industry's authoritative CAP CLIA qualification and a third-party medical laboratory certified by China CNAS ISO15189, with a service network covering more than 70% of the core tertiary hospitals, serving more than 800 hospitals, providing precision medicine management products and services from early diagnosis of diseases, companion diagnosis to dynamic monitoring of diseases.
Combined with years of experience in pathological detection and artificial intelligence algorithm technology, Shanghai Shuda Data Technology, a subsidiary of Idea Di Diagnostics, is committed to providing diversified pathological image analysis software for the majority of medical workers and scientific research workers, and providing easy-to-operate artificial intelligence tools for clinicians engaged in medical image research and diagnosis.